{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T02:46:28Z","timestamp":1774579588439,"version":"3.50.1"},"reference-count":16,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,6]],"date-time":"2024-04-06T00:00:00Z","timestamp":1712361600000},"content-version":"vor","delay-in-days":706,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Medicine"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.7861\/clinmed.2022-0150","type":"journal-article","created":{"date-parts":[[2022,5,18]],"date-time":"2022-05-18T09:05:20Z","timestamp":1652864720000},"page":"225-229","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Lymphocytosis and chronic lymphocytic leukaemia: investigation and management"],"prefix":"10.1016","volume":"22","author":[{"given":"Amarpreet","family":"Devi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lieze","family":"Thielemans","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eleni E","family":"Ladikou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taran K","family":"Nandra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timothy","family":"Chevassut","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.7861\/clinmed.2022-0150_bib1","author":"BMJ Best Practice","year":"2022","journal-title":"Chronic lymphocytic leukaemia"},{"key":"10.7861\/clinmed.2022-0150_bib2","author":"GP Notebook","year":"2022","journal-title":"Lymphocytosis"},{"key":"10.7861\/clinmed.2022-0150_bib3","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1111\/bjh.12067","article-title":"Guidelines on the diagnosis, investigation and management of chronic lymphocytic leukaemia","volume":"159","author":"Oscier","year":"2012","journal-title":"Br J Haematol"},{"key":"10.7861\/clinmed.2022-0150_bib4","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.annonc.2020.09.019","article-title":"Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"32","author":"Eichhorst","year":"2020","journal-title":"Ann Oncol"},{"key":"10.7861\/clinmed.2022-0150_bib5","series-title":"WHO classification of tumours of haematopoietic and lymphoid tissues, fourth edition","author":"Swerdlow","year":"2017"},{"key":"10.7861\/clinmed.2022-0150_bib6","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1038\/leu.2017.125","article-title":"Immunoglobulin gene sequence analysis in chronic lymphocytic leukemia: updated ERIC recommendations","volume":"31","author":"Rosenquist","year":"2017","journal-title":"Leukemia"},{"key":"10.7861\/clinmed.2022-0150_bib7","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/S1470-2045(16)30029-8","article-title":"An international prognostic index for patients with chronic lymphocytic leukaemia (CLL-IPI): a meta-analysis of individual patient data","volume":"17","author":"International CLL-IPI working group","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.7861\/clinmed.2022-0150_bib8","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1182\/blood-2017-09-806398","article-title":"iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL","volume":"131","author":"Hallek","year":"2018","journal-title":"Blood"},{"key":"10.7861\/clinmed.2022-0150_bib9","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1002\/1097-0142(19810701)48:1<198::AID-CNCR2820480131>3.0.CO;2-V","article-title":"A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis","volume":"48","author":"Binet","year":"1981","journal-title":"Cancer"},{"key":"10.7861\/clinmed.2022-0150_bib10","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1182\/blood.V46.2.219.219","article-title":"Clinical staging of chronic lymphocytic leukemia","volume":"2","author":"Rai","year":"1975","journal-title":"Blood"},{"key":"10.7861\/clinmed.2022-0150_bib11","first-page":"115","article-title":"Chronic lymphocytic leukemia: prognostic factors and impact on treatment","volume":"11","author":"Parker","year":"2011","journal-title":"Discov Med"},{"key":"10.7861\/clinmed.2022-0150_bib12","doi-asserted-by":"crossref","first-page":"4634","DOI":"10.1200\/JCO.2006.06.9492","article-title":"Prospective evaluation of clonal evolution during long-term follow-up of patients with untreated early-stage chronic lymphocytic leukemia","volume":"24","author":"Shanafelt","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.7861\/clinmed.2022-0150_bib13","series-title":"Venetoclax with obinutuzumab for untreated chronic lymphocytic leukaemia: Technology appraisal guidance [TA663]","author":"National Institute for Health and Care Excellence","year":"2020"},{"key":"10.7861\/clinmed.2022-0150_bib14","series-title":"Fludarabine monotherapy for the first-line treatment of chronic lymphocytic leukaemia: Technology appraisal guidance [TA119]","author":"National Institute for Health and Care Excellence.","year":"2007"},{"key":"10.7861\/clinmed.2022-0150_bib15","unstructured":"Cancer Research UK, . Patient agreement to systemic anti-cancer therapy (SACT): FCR (Fludarabine-Cyclophosphamide-Rituximab). Cancer Research UK. www.cancerresearchuk.org\/sites\/default\/files\/cancer-stats\/cll_fcr_3_days_v1\/cll_fcr_3_days_v1.pdf [Accessed 20 February 2022]."},{"key":"10.7861\/clinmed.2022-0150_bib16","author":"National Institute for Health and Care Excellence","year":"2022","journal-title":"Venetoclax for treating chronic lymphocytic leukaemia [ID944]: Committee papers"}],"container-title":["Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1470211824029579?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1470211824029579?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.7861\/clinmed.2022-0150","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,12]],"date-time":"2025-04-12T08:42:25Z","timestamp":1744447345000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1470211824029579"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":16,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["S1470211824029579"],"URL":"https:\/\/doi.org\/10.7861\/clinmed.2022-0150","relation":{},"ISSN":["1470-2118"],"issn-type":[{"value":"1470-2118","type":"print"}],"subject":[],"published":{"date-parts":[[2022,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lymphocytosis and chronic lymphocytic leukaemia: investigation and management","name":"articletitle","label":"Article Title"},{"value":"Clinical Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.7861\/clinmed.2022-0150","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 Royal College of Physicians 2022. All rights reserved.","name":"copyright","label":"Copyright"}]}}